IDF 2013

Flash Glucose Monitoring and Ambulatory Glucose Profile (AGP): EXPANDING THE GLUCOSE STORY BEYOND A1C

Chair: Richard M. Bergenstal, M.D., Executive Director, International Diabetes Center, USA

1. AGP: An evidence-based system for sensor data interpretation
 

mazze-sm.jpg

Roger S. Mazze

Ph.D. International Diabetes Center (USA)

Dr Roger S. Mazze is Senior Vice President of Park Nicollet Institute and Chief Academic Officer of the International Diabetes Center (IDC), where he has been based since 1988. He is also Head of the WHO Collaborating Center at the IDC and Mayo Clinic.

During his time at the IDC Dr Mazze developed Staged Diabetes Management (SDM), a systematic approach to the prevention, detection and management of diabetes and its complications. Currently, SDM is in use in more than 20 countries. He also built the WHO Technology Laboratory, which was the first to be devoted to advancing computer technologies in diabetes, and continues to develop the AGP as a common reporting structure for CGM. On-going work to create an automated AGP report, supported in part by the Helmsley Foundation, will enable clinicians and patients to have the ability to rapidly access CGM data for clinical decision-making, treatment efficacy assessment, and the measurement of short and long-term clinical outcomes.

A pioneer in the world of glucose monitoring, Dr Mazze has written extensively on SMBG and CGM, clinical decision-making, advanced insulin delivery systems, and algorithms for diabetes management. In recognition of these contributions he has served as visiting professor, most recently at Nanjing Medical University where he continues research with collaborators in areas of clinical care, prevention, diabetes in pregnancy and epidemiology. Dr Mazze has presented at national and international forums in more than 40 countries.

2. Using sensor data in clinical practice, the value of AGP
 

bergenstal-sm.jpg

Richard M. Bergenstal

International Diabetes Center, Minneapolis, US

Dr Richard M. Bergenstal, MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. He is Clinical Professor in the Department of Medicine at the University of Minnesota and served as President, Medicine and Science of the American Diabetes Association in 2010. In 2007, Dr Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year.

Dr Bergenstal received his MD and endocrine training from the University of Chicago where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983. His clinical research has focused on glucose control and diabetes complications and he serves as a Principal Investigator of three NIH trials: the DCCT/EDIC in T1D, the ACCORD follow-up, and GRADE studies in T2D. He studies the effective utilisation of insulin therapy, glucose monitoring (SMBG and CGM), and other new technologies to improve glucose control and clinical outcomes. He teaches nationally and internationally on the importance of developing new models of care built around patient-centred team care. He has been listed in Best Doctors in America since it began in 1992, published over 180 peer reviewed scientific articles, and has co-authored the best-selling Betty Crocker Diabetes Cookbook.

3. Value of AGP in clinical decision-making and therapy management of diabetes
 

wolpert-sm.jpg

Howard Wolpert

M.D. Joslin Diabetes Center (USA)

Dr Howard Wolpert is Senior Physician in the Section of Adult Diabetes at the Joslin Diabetes Center/Harvard Medical School, and is Director of the recently established Transitional Center for Technology and Connectivity in Diabetes Care.

Dr Wolpert’s research and clinical interests focus on the use of technology in
diabetes care and enhancing patient adherence, and he established the Insulin Pump and CGM Programs at Joslin (which now follow over 2,000 and 600 patients, respectively). He is the author of Smart Pumping, a guide book on insulin pump therapy, and Transitions in Care, a guidebook focusing on the issues and challenges faced by young adults during the transition to independent diabetes self-care, both published by the American Diabetes Association. He has published widely especially on CGM, including an invited editorial in the New England Journal of Medicine, invited chapters in major texts, and has also presented invited lectures at the International Diabetes Federation meeting, Scientific Sessions of the Annual Meetings of the American Diabetes Association, as well as FDA panel hearings.

4. AGP: Real-world experience
 

Oliver_Schubert_Photo_3.jpg

Oliver Schubert

Diabetes Care Centre, Buxtehude (Germany)

Dr Schubert completed his medical studies in Hamburg and Leipzig from 1993 to 1999 before moving onto an internship in internal medicine, surgery and orthopedics at Elbeklinikum Buxtehude and Diakonieklinikum Rotenburg until 2006. Thereafter he completed studies in internal medicine and diabetology at the Bethanion Hospital, Hamburg and Klinik Bremen Nord. Dr Schubert was Head of the DDB (German Diabetes Union), for the Buxtehude district from 2008 to 2012, during which time his focus was on patient education and the integration of diabetes into daily life. His clinical interests are diabetes and technologies such as insulin-pump therapy, CGM and glucometers including bolus calculators. Dr Schubert remains keen to pursue the integration of technology into patients’ lives with the goal of making diabetes less stressful.

5. Flash Glucose Monitoring: Next generation sensor-based system for diabetes management

Steve_Scott.jpg

Steven Scott

Division Vice President R&D, Abbott Diabetes Care (USA)

Steven Scott is Divisional Vice President of Research and Development at Abbott Diabetes Care.

Steve joined MediSense, later acquired by Abbott, in 1986 as a project scientist and during his 27 year tenure with the company has contributed to the development of many glucose monitoring products ranging from MediSense’s first blood glucose monitoring system, the ExacTech, launced in 1987, to today’s rapid test time, no calibration-required FreeStyle blood glucose systems. Steve was also involved in the development of ZipWickTM technology to enable easier blood application onto testing strips. He is currently involved in enhancing ADC’s sensor-based technology. He was appointed to his current role in 2002.

The Revolution will be Bloodless